The FREEDOM trial: in appropriate patients with diabetes and multivessel coronary artery disease, CABG beats PCI.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 23908108.
- Also identified by DOI 10.3949/ccjm.80a.13030.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial (N Engl J Med 2012; 367:2375-2384) was designed to resolve the long-standing debate over the optimal revascularization strategy in patients with diabetes mellitus and multivessel coronary artery disease. At a median follow-up of 3.8 years, the incidence of the primary outcome (a composite of death, myocardial infarction, and stroke) was significantly lower with bypass surgery than with percutaneous intervention.
Medical subject headings
- Coronary Artery Bypass
- Coronary Artery Disease
- Diabetes Complications
- Percutaneous Coronary Intervention